published meta-analysis   sensitivity analysis   studies

Vitamin D in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsCOVIT-TRIAL, 2022 (REV) 1.84 [0.74; 4.56] 1.84[0.74; 4.56]COVIT-TRIAL, 2022 (REV)10%254NAnot evaluable death D28detailed resultsCOVIT-TRIAL, 2022 (REV) 1.13 [0.57; 2.22] 1.13[0.57; 2.22]COVIT-TRIAL, 2022 (REV)10%252NAnot evaluable deathsdetailed resultsCOVID-VIT-D, 2022 1.48 [0.75; 2.92] COVIT-TRIAL, 2022 (REV) 1.13 [0.57; 2.22] Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79] Murai, 2020 1.53 [0.53; 4.43] 1.27[0.82; 1.95]COVID-VIT-D, 2022, COVIT-TRIAL, 2022 (REV), Entrenas (Pilot Calcifediol), 2020, Murai, 202040%1,108seriousnot evaluable hospital dischargedetailed resultsMurai, 2020 0.99 [0.71; 1.38] 0.99[0.71; 1.38]Murai, 202010%240NAnot evaluable mechanical ventilationdetailed resultsMurai, 2020 0.49 [0.21; 1.14] 0.49[0.21; 1.14]Murai, 202010%237NAnot evaluable viral clearance detailed resultsRastogi, 2020 6.33 [1.54; 26.00] 6.33[1.54; 26.00]Rastogi, 202010%40NAnot evaluable ICU admissiondetailed resultsEntrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27] Murai, 2020 0.71 [0.37; 1.37] 0.17[0.01; 3.79]Entrenas (Pilot Calcifediol), 2020, Murai, 2020286%313moderatenot evaluable serious adverse eventsdetailed resultsMurai, 2020 0.99 [0.02; 50.39] 0.99[0.02; 50.39]Murai, 202010%237NAnot evaluable adverse eventsdetailed resultsMurai, 2020 1.99 [0.07; 59.94] 1.99[0.07; 59.94]Murai, 202010%237NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-03 02:01 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 734,1439 - roots T: 290